Sugi Predict

Sugi Predict / Targets / BCL9

BCL9

B-cell CLL/lymphoma 9 protein · O00512 · BCL9 on Sugi Atlas →

18,053 patent compounds predicted against BCL9, 10,182 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL478100 SCHEMBL478100 0.53 15/20
SCHEMBL478136 SCHEMBL478136 0.53 14/20
SCHEMBL478039 SCHEMBL478039 0.49 13/20
SCHEMBL478086 SCHEMBL478086 0.46 13/20
SCHEMBL478167 SCHEMBL478167 0.43 10/20
Quercetin-3'-O-Phosphate Quercetin-3'-O-Phosphate (SCHEMBL118113) 0.67 9/20
SCHEMBL117682 SCHEMBL117682 0.65 9/20
SCHEMBL507435 SCHEMBL507435 0.60 8/20
SCHEMBL412179 SCHEMBL412179 0.54 8/20
Gossypetin Gossypetin (SCHEMBL157033) 0.73 7/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL72907) 0.49 7/20
Herbacetin Herbacetin (SCHEMBL872691) 0.67 6/20
SCHEMBL171665 SCHEMBL171665 0.48 6/20
SCHEMBL241094 SCHEMBL241094 0.48 6/20
SCHEMBL442344 SCHEMBL442344 0.47 6/20
SCHEMBL118236 SCHEMBL118236 0.44 6/20
SCHEMBL411999 SCHEMBL411999 0.41 5/20
SCHEMBL112968 SCHEMBL112968 0.32 5/20
SCHEMBL542953 SCHEMBL542953 0.49 4/20
SCHEMBL171529 SCHEMBL171529 0.44 4/20

Clinical trials — most relevant to BCL9 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Fludarabine With or Without Cyclophosphamide in Treating Patients With Chronic Lymphocytic Leukemia PHASE3COMPLETED
Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia PHASE1/PHASE2ACTIVE_NOT_RECRUITING
SPC2996 in Chronic Lymphocytic Leukaemia PHASE1/PHASE2COMPLETED
BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma PHASE1/PHASE2RECRUITING
Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma PHASE2RECRUITING
Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia PHASE1/PHASE2COMPLETED
DALY II Japan/MB-CART2019.1 for DLBCL PHASE2RECRUITING
Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL PHASE2ACTIVE_NOT_RECRUITING
Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL PHASE1/PHASE2ACTIVE_NOT_RECRUITING
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma PHASE2RECRUITING
CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma PHASE1/PHASE2RECRUITING
Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma PHASE1ACTIVE_NOT_RECRUITING
Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies PHASE1UNKNOWN
Safe Accelerated Venetoclax Escalation in CLL PHASE1ACTIVE_NOT_RECRUITING
T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies PHASE1COMPLETED
Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell Lymphoma PHASE1UNKNOWN
CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT PHASE1UNKNOWN
Safety and Efficacy Evaluation of IM19 Cells PHASE1UNKNOWN
Safety and Efficacy of KSVCBD Injection in B-cell Non-Hodgkin's Lymphoma Expressing CD19 and/or BCMA PHASE1RECRUITING
PS-341 in Treating Patients With Hematologic Cancer PHASE1COMPLETED
Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma PHASE1WITHDRAWN
Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma PHASE1COMPLETED
MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM) PHASE1ACTIVE_NOT_RECRUITING
A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies EARLY_PHASE1UNKNOWN
Notch 1 Mutation in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patient nanNOT_YET_RECRUITING
Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch nanNO_LONGER_AVAILABLE
Clinical-biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Under Ibrutinib-named Patient Program nanCOMPLETED
French Observational Study of Patients With Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma in Real-World Settings nanACTIVE_NOT_RECRUITING
Determinants of the Response to BTK Degraders (BTKd) in Chronic Lymphocytic Leukemia nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a BCL9 binder may also engage these)

ProteinNameSimilarity
Q9D219 — 1.000 Q9D219 →
Q67FY3 — 1.000 Q67FY3 →
BCL9L B-cell CLL/lymphoma 9-like protein (B-cell ly 0.997 landscape →
Q67FY2 — 0.996 Q67FY2 →
Q9R050 — 0.993 Q9R050 →
EP300 Histone acetyltransferase p300 0.992 landscape →
P0CB49 — 0.992 P0CB49 →
P40645 — 0.992 P40645 →
B2RWS6 — 0.991 B2RWS6 →
Q9R0I7 — 0.991 Q9R0I7 →
D3YWE6 — 0.991 D3YWE6 →
Q9CYZ8 — 0.990 Q9CYZ8 →
Q9BTA9 — 0.990 Q9BTA9 →
Q961D9 — 0.990 Q961D9 →
Q8R5I7 — 0.989 Q8R5I7 →
Q7ZUK7 — 0.989 Q7ZUK7 →
Q14686 — 0.989 Q14686 →
O35126 — 0.989 O35126 →
A3RK74 — 0.989 A3RK74 →
P81877 — 0.988 P81877 →
P40647 — 0.988 P40647 →
Q9P267 — 0.988 Q9P267 →
A2AJK6 — 0.988 A2AJK6 →
A0A0G2JTZ2 — 0.988 A0A0G2JTZ2 →
O14497 — 0.988 O14497 →
A3RK75 — 0.988 A3RK75 →
Q810W5 — 0.988 Q810W5 →
Q6EUW2 — 0.988 Q6EUW2 →
P34545 — 0.988 P34545 →
Q5RCU4 — 0.988 Q5RCU4 →